Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
Pierre D. Delmas(Inserm), Steven Boonen(KU Leuven), Rachelle Eusebio(Procter & Gamble (United States)), David E. Burgio(Procter & Gamble (United States)), Christian Roux(Hôpital Pasteur), John F. Beary(Procter & Gamble (United States)), Artur Racewicz, Z. Man(Merck & Co., Inc., Rahway, NJ, USA (United States)), José Zanchetta(Universidad del Salvador), Claude-Laurent Benhamou(Inserm), Michael R. McClung(Bone Health and Osteoporosis Foundation)
Cited by 97
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women
|New England Journal of Medicine|1997|1.6k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k
Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis
|Journal of Bone and Mineral Research|2004|1.2k